This post was originally published on this site “Oh, by the way,” she said nonchalantly as I entered the room. “Your scans are clear.” “I’m sorry, what?” I stuttered in disbelief. Just like that, in a matter of seconds, my oncologist revealed the news I had waited, hoped, and prayed over a year for. Four…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ImmunityBio‘s interleukin-15 (IL-15) agonist N-803, in combination with Bacillus Calmette-Guerin (BCG) for the treatment of non-muscle invasive bladder carcinoma in situ (CIS) that does not respond to BCG treatment alone. The designation is intended…
This post was originally published on this site A U.S. Department of Health and Human Services grant will fund research at two universities into whether an ultrasound technology might be more effective than mammography at detecting breast cancer, particularly in younger people. At present, mammography is most often used to screen for and diagnose breast cancers.…
This post was originally published on this site Trovagene’s investigational oral therapy onvansertib may help overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), updated Phase 2 data continue to suggest. The trial (NCT03414034) is testing onvansertib as an add-on to Zytiga (by Janssen Biotech) and prednisone in men who experienced…
This post was originally published on this site Oral Lynparza (olaparib) has been approved in China as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer who responded to initial platinum-based chemotherapy, AstraZeneca and Merck (known as MSD outside the U.S. and Canada) announced. Lynparza is now the first PARP enzyme inhibitor approved in that…
This post was originally published on this site A combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone, given before and immediately after a stem cell transplant, is effective for the treatment of patients with smoldering multiple myeloma — a precursor condition to multiple myeloma — at high risk of progressing to the full blown disease,…
This post was originally published on this site Despite skyrocketing healthcare costs, President Trump is committed to protecting the 30 million or so Americans with rare diseases and ensuring timely, affordable access to lifesaving treatments, the nation’s highest-ranking health official said. “We have to think about how our financing system can protect those with serious…
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) in combination with chemotherapy — Abraxane (nab-paclitaxel) plus carboplatin — as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors do not have any mutations in the EGFR or ALK genes. Tecentriq is…
This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that Kadcyla (ado-trastuzumab emtansine) be approved as an adjuvant (post-surgery) treatment for certain HER2-positive early breast cancers, the treatment’s maker, Genentech, has announced. Specifically, the advisory committee for the European Union’s…
This post was originally published on this site Treatment with Myovant Sciences’ relugolix induces a long-lasting reduction in testosterone to castrate levels — similar to testosterone levels after medical or chemical castration — in nearly all men with advanced prostate cancer who are sensitive to androgen deprivation therapy, updated results from the HERO Phase 3…
